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Abstract Mutations in the gene encoding the mitochon-
drial protein high temperature requirement A2 (HTRA2)
are inconsistently associated with a risk of Parkinson’s
disease (PD). We assessed the presence of HTRA2 muta-
tions among patients with PD and performed functional
assay of identiﬁed mutations or variants. Among the total
1,373 subjects, the entire HTRA2 coding region was
sequenced in 113 early-onset PD (EOPD), 20 familial PD
patients and 150 control subjects. An additional 390 spo-
radic late-onset PD patients and 700 controls were subse-
quently screened to validate possible mutations found in
the ﬁrst set. We identiﬁed two novel heterozygous variants,
c.427C[G (Pro143Ala) and c.906 ?3G[A, in 2 (1.5%)
EOPD patients. The missense variant, Pro143Ala, was also
observed in one late-onset PD patient but was absent
in total 850 control subjects (relative risk 2.3, 95% CI
1.5–2.8, P = 0.04). Expressing Pro143Ala variant of
HTRA2 in primary dopaminergic neurons causes neurite
degeneration. Following exposure to rotenone, the ultra-
structural mitochondrial abnormality, the percentage of
mitochondrial dysfunction and apoptosis in cells carrying
the HTRA2 Pro143Ala variant was signiﬁcantly higher
than wild-type cells. Mechanistically, protein level of
phosphorylated HTRA2 was increased in cells carrying the
Pro143Ala variant, suggesting Pro143Ala variant promotes
HTRA2 phosphorylation with resultant mitochondrial
dysfunction. Our results support a biologically relevant role
of HTRA2 in PD susceptibility in Taiwanese. Further large-
scale association studies are warranted to conﬁrm the role
of HTRA2 Pro143Ala variant in the risk of PD.
Introduction
Parkinson’s disease (PD) is one of the most common
neurodegenerative disorders and is characterized by intra-
neuronal a-synuclein-positive aggregations (Forno 1996).
Mutations in a number of pathogenic genes (e.g., SNCA,
Parkin, UCHL1, DJ-1, PINK1, ATP13A2, and LRRK2)
have been associated with both familial and sporadic PD
(for review, see Lesage and Brice 2009). Both mitochon-
drial dysfunction and ubiquitin–proteasome system damage
have been proposed as possible mechanisms leading to
dopaminergic neuronal degeneration (Lin and Beal 2006;
Rubinsztein et al. 2006; Malkus et al. 2009). The role of
mitochondria in PD was ﬁrst noticed with the description
of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
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DOI 10.1007/s00439-011-1041-6toxicity causing PD in humans, and was later supported by
the association of several PD causative genes, including
PINK1 and DJ-1, with mitochondrial dysfunction
(Langston and Ballard 1983; Bonifati et al. 2003; Valente
et al. 2004).
Recent identiﬁcation of Omi/HTRA2 (MIM# 606441) as
a novel PD locus (PARK13) has further supported the role
of mitochondrial dysfunction in PD pathogenesis (Strauss
et al. 2005). High temperature requirement A2 (HTRA2)-
mutant mice present a progressive neurodegenerative
phenotype with parkinsonism features (Jones et al. 2003).
HTRA2 encodes a 50-kDa serine protease that localizes to
the mitochondrial intermembrane space (IMS) and protects
cells from apoptotic stimuli by either preventing the
accumulation of damaged protein in the mitochondria
directly or exposing an inhibitor of apoptosis protein (IAP)
binding motif to antagonize the interaction with cytosolic
IAP-caspase (Weibezahn et al. 2004). A subsequent genetic
study of PD patients found that a heterozygous mutation of
HTRA2, Arg404Trp, is associated with the development of
PD (Bogaerts et al. 2008). However, further study of a
North American case–control series detected the same
potential HTRA2 mutation in healthy control subjects
(Simon-Sanchez and Singleton 2008). Another mutation
screen performed in German PD patients showed an
association between the Ala141Ser polymorphism near the
protease domain and the risk of PD but no association for
the G399S variant (Strauss et al. 2005). Nevertheless, one
large-scale association study revealed no association of ﬁve
known HTRA2 polymorphisms with PD in mixed popula-
tions, including a small sample size of Taiwanese patients
(Kru ¨ger et al. 2009). However, one recent study conducted
in the Chinese population showed an association of one
intronic variant with risk of PD (Wang et al. 2011). These
inconsistent ﬁndings raise a question about the role of
mitochondrial HTRA2 in PD susceptibility. Furthermore, to
date, the functional evidence for possible HTRA2 risk
variants in neuronal toxicity is still unclear.
To elucidate the contribution of HTRA2 in PD patho-
genesis, we investigated HTRA2 mutations in PD patients
of Taiwanese origin. Our group has previously performed a
comprehensive analysis of mutations in multiple candidate
genes in a cohort of early-onset PD (EOPD) patients of
Taiwanese origin (Lockhart et al. 2004; Wu et al. 2005;
Lin et al. 2008a, b ; Lee et al. 2009). However, the major
genetic causes in the majority of EOPD patients in our
population are still unclear. The recent identiﬁcation of
HTRA2 polymorphisms as a risk factor in PD patients
suggests that rare genetic variants may play a role in some
populations. Although the disease onset age of originally
reported PD patients with potential HTRA2 mutations
were not totally early-onset (range 49–77 years, mean
57.3 years, Strauss et al. 2005), we sequenced the complete
HTRA2 coding region in a cohort of 133 Taiwanese
patients with EOPD or familial PD and 150 age- and
gender-matched controls in the ﬁrst study set. We then
conﬁrmed the relevance of the identiﬁed risk substitutions
in a large-scale case series of late-onset PD patients. We
also conducted in vitro functional assays to examine the
potential toxicity of identiﬁed HTRA2 variants on mito-
chondria in neurons.
Materials and methods
Subjects
A total of 1,373 subjects were included in this study: 523
PD patients (113 early-onset PD (EOPD) patients, 20
familial PD (FPD) patients, and 390 sporadic late-onset PD
patients and 850 control subjects who exhibited no evi-
dence of PD. All PD patients were recruited from the
Movement Disorder Clinic of the National Taiwan Uni-
versity Hospital, a tertiary referral center in Taiwan. Of the
133 probands enrolled in the ﬁrst set of the study, 113 were
sporadic EOPD patients (onset before 50 years of age) and
the remaining 20 were FPD patients with a family history
of the disease (at least one affected ﬁrst- and/or second-
degree relatives with parkinsonism). None of the subjects
were from consanguineous families. The majority of the
EOPD and FPD patients were ever screened for mutations
of Parkin, PINK1, DJ-1 and ATP13A2 (Lockhart et al.
2004; Wu et al. 2005; Lin et al. 2008a, b; Lee et al. 2009).
All patients fulﬁlled the diagnostic criteria for PD (Gelb
et al. 1999). The patients received standard neurological
examinations, including the Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS) and Mini-Mental Status Evaluation
(MMSE) (Folstein et al. 1975). Relatives of the probands
carrying the HTRA2 Pro143Ala substitution were also
subjected to the University of Pennsylvania Smell Identi-
ﬁcation Test (UPSIT) (Doty et al. 1984). Among the 850
control subjects, 500 controls are healthy spouses or care-
givers of PD patients without neurological signs and the
other 350 control subjects were end stage renal disease
patients under regular dialysis without any symptoms or
signs of PD. Informed consent was obtained from all par-
ticipants. The study was approved by the institutional
ethics board committees.
HTRA2 screening in PD and control subjects
Complete sequencing of HTRA2 was carried out in 133
EOPD and familial PD patients and 150 age-, gender-, and
ethnicity-matched controls. To further clarify the associ-
ation of the novel HTRA2 substitution identiﬁed in the ﬁrst
part of the screening, the second part of the study was
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123performed using an additional 390 independent sporadic
OPD patients and 700 control subjects. Genomic DNA
was extracted from venous blood using standard protocols.
The eight exons and intron–exon boundaries of HTRA2
were ampliﬁed using polymerase chain reaction (PCR) and
sequenced by ABI 3730 (Applied Biosystems). The primer
sequences and PCR conditions were as previously
described (Bogaerts et al. 2008). Base variants were
labeled from the ATG start of protein translation
(NM_013247.4).
Relative quantiﬁcation of HTRA2 gene expression
and RT-PCR analysis in subjects with HTRA2 c.906 ?3
G[A variation
To clarify whether the potential pathogenic variation in the
exon–intron boundary junction, c.906 ?3G[A, disrupts
splicing efﬁcacy of HTRA2, we performed quantitative
real-time PCR (q-PCR) and reverse transcription PCR (RT-
PCR) analyses to check the gene expression of HTRA2 in
one of our EOPD patient, labeled as Y63, and seven age-/
gender-matched control subjects. Total RNA was extracted
from human whole blood using the QIAamp
 RNA Blood
Mini Kit (Qiagen, USA) and reverse transcription was
performed using the Reverse Transcription System Kit
(Promega, USA) according to the manufacturer’s instruc-
tions. For q-PCR analysis, the sequences of the primer
pairs were: HTRA2, forward 50- GTGGCAGACATCGC
AACGCT -30, reverse 50- ACCCACTGATTCCGGAG-
GAG - 30; hGAPDH, forward 50- ATGGGTGTGAACCAT
GAGAAG - 30, reverse 50- AGTTGTCATGGATGACCTT
GG - 30. Thermal cycler conditions were 30 s at 95C
followed by 40 cycles of 5 s at 95C to denature the DNA,
10 s at 55C to anneal, and 15 s at 60C to extend the
template. All reactions were performed in triplicate. The
values obtained for the expression of the target gene were
normalized to GAPDH and quantiﬁed relative to the
expression in control samples. For the relative quantiﬁ-
cation, the 2 DDCT formula was used, where -DDCT =
(CT, target - CT, GAPDH) experimental sample - (CT, target -
CT, GAPDH) control sample. For RT-PCR analysis, the
sequences of the primer pairs were: HTRA2, forward
50-GTGGCAGACATCGCAACGCT-30, reverse 50-ACCC
ACTGATTCCGGAGGAG-30; hGAPDH, forward 50-ATG
GGTGTGAACCATGAGAAG-30, reverse 50-AGTTGTCA
TGGATGACCTTGG-30.A2 0 ll PCR contained 50 ng
cDNA, 0.25 lM of each primer and 10 ll2 9 GoTaq
Green Master Mix (Promega). Thermal cycler parameters
were 35 cycles at 95C for 30 s, annealing at 55C for 30 s,
and 72C for 35 s, with preheat at 95C for 2 min 30 s and
last extension at 72C for 7 min. The reaction was per-
formed in triplicate.
In silico modeling of the crystal structure of HTRA2
with and without the Pro143Ala variation
The crystal structure of Omi/HTRA2 (1LCY), from which
the N-terminal 133 residues were removed, was obtained
from the RSCB protein data bank. The mutated model was
generated using DS/Build Mutant Mutants (Discovery
Studio 2.1, Accelrys Software, San Diego). The three-
dimensional structural model was constructed based on the
structure of 1LCY. Residue 143 was selected and assigned
to be the Ala residue, and the loop region of residues
139–149 was optimized using the MODELER program.
The model was calculated by default parameters, and the
non-bonded Melo’s potential was adapted for loop
reﬁnement.
In vitro Functional assay of HTRA2 Pro143Ala
variation
Construction of HTRA2 expression plasmids
and transfection in neuronal cells
To explore the effects of potential pathogenic variation of
HTRA2, Pro143Ala, in the cells, we constructed both wild-
type and variant HTRA2 plasmids and performed a series of
functional assay in transfected neurons. Human HTRA2
cDNA was constructed from venous blood of healthy
controls and cloned into the pCR
8/GW/TOPO
 vector
(Invitrogen) using the primers 50-ACTTCTGAAGGACT
TCAGGTACCGGCGTGC-30 and 50-GAAAGGCAAGG
AGGAAATCAGAGCAGGAGCC-30. The c.427C[G
(Pro143Ala) variant of HTRA2 was generated by PCR-
mediated site-directed mutagenesis (Stratagene). The
integrity of the construct was conﬁrmed by direct DNA
sequencing. The wild-type and variant HTRA2 were then
sub-cloned into the pcDNA-DEST47 vector (Invitrogen)
in-frame with the eGFP coding sequences.
The transient transfection of HTRA2 plasmid was per-
formed in both human dopaminergic neuroblastoma cell
line (SH-SY5Y) and rat primary dopaminergic neuronal
culture. SH-SY5Y cell line was maintained at 37Ci na
humidiﬁed 95% air/5% CO2 incubator and grown on
polyornithine-precoated 6-well plates in MEM/F12 med-
ium (Invitrogen) containing 10% fetal bovine serum and
2m M L-glutamine. Embryonic day 14 (E14) mesence-
phalic cells were obtained from rat fetuses and were
incubated in Ca
2?,M g
2?-free HBSS containing papin at
37C for 30 min. The dissociated cells were then fed with
Neurobasal media containing B27 supplement. Both types
of neurons were transfected overnight with pcDNA/
GW-47/CAT vector and different HTRA2 plasmids using
FuGENE HD (Roche Applied Science) according to the
Hum Genet (2011) 130:817–827 819
123manufacturer’s instructions. These transfected cells were
then used for the following experiments.
Localization of HTRA2 protein and quantiﬁcation
of neurite outgrowth in primary dopaminergic
neuron culture
To elucidate whether the variant HTRA2 changes the local-
ization of the encoded protein in mitochondria, we used
immunohistochemistry assay to recognize the localization of
HTRA2 protein in both SH-SY5Y and rat primary dopami-
nergic neurons. The transfected cells were stained with
500 nM MitoTracker Red CMXRos (Molecular Probes)
according to the manufacturer’s instructions. Cells were also
co-stained with nucleus marker, DAPI (0.1 lg/ml), for
30 min and then mounted with CC/Mount
TM
Aqueous
Mounting Medium (Sigma). These cells were observed by
confocal laser scanning microscopy (LSM510 Meta, Zeiss).
Given that change of neurite morphology is often the
preceding feature of neuron damage (Takeuchi et al. 2005),
we next examined the effect of HTRA2 Pro143Ala variant
on neurite arborization in rat primary dopaminergic neu-
rons. For the quantiﬁcation of neurite outgrowth in neu-
rons, at least 17 confocal images of tyrosine hydroxylase
(TH)-positive cells per condition were taken at 409 mag-
niﬁcation. The measurement of neurite length was carried
out using the NIH freeware Image-J starting where the
neurite emerges from the cell body and tracing its length
out to the distal tip.
Flow cytometric analysis of mitochondrial membrane
potential and apoptosis induced by rotenone
To investigate the effect of HTRA2 Pro143Ala variant on
mitochondrial function, we investigate the change of
mitochondrial membrane potential (MMP) in SH-SY5Y
cells transfected with the wild-type or Pro143Ala variant
HTRA2 by ﬂow cytometric analysis using the probe
3,3’-dihexyloxacarbocyanine iodide (DiOC6(3) (Invitro-
gen). Furthermore, the transfected SH-SY5Y neurons were
treated with rotenone, a mitochondria complex I inhibitor,
at 50, 100, and 300 nM to test the vulnerability of cells to
this speciﬁc mitochondrial neurotoxin. The percentage of
cell apoptosis was assessed by ﬂow cytometry using the
annexin V (AV)-FITC/propidium iodine (PI) apoptosis
detection kit (Strong Biotech Co.) as previously described
(Lin et al. 2008a, b).
Transmission electron microscopy (TEM) imaging
of mitochondrial morphology
The ultra-structure of SH-SY5Y cells was obtained using
transmission electron microscopy. Cells were brieﬂy rinsed
in 19 phosphate-buffered saline, pH 7.4, and then ﬁxed in
2.5% glutaraldehyde in the same buffer overnight at 4C.
They were then rinsed again and post-ﬁxed with 1%
osmium tetroxide in buffer, for 30 min at room temperature.
After rinsing with buffer, slides were dehydrated in ethanol.
Cells were then inﬁltrated with graded mixtures of propyl-
ene oxide/Spurr’s resin, and embedded in the same resin,
allowing specimens to polymerize at 70C for 8 h. Blocks
were cut by a Reichert Ultracut S ultramicrotome, thus
obtaining ultrathin sections (70 nm) which were collected
on nickel grids. Grids were stained with uranyl acetate and
then followed by staining with lead citrate. Sections were
examined in a Hitachi H7100 electron microscope.
Immunoprecipitation assay of phospho-HTRA2 protein
It is known that the phosphorylation status of HTRA2
protein correlates with its anti-apoptotic activity (Plun-
Favreau et al. 2007). It is therefore important to examine
whether Pro143Ala substitution affects the phosphorylation
level of HTRA2 protein. We thus examine the phospho-
HTRA2 protein level using SPM101 antibody (Gene Tex)
that speciﬁcally recognizes phosphorylated serine/threo-
nine/tyrosine sites of protein to perform immunoprecipi-
tation (IP) assay in SH-SY5Y cell lysate transiently
expressing either wild-type or Pro143Ala variant HTRA2.
The ectopic HTRA2 protein in the IP efﬂuent was analyzed
by western blot using anti-eGFP antibody.
Statistical analysis
All experiments were repeated at least three times. The
data were expressed as mean ± standard error (SE) in the
functional assay. Categorical variables were analyzed using
the Chi-square test. Numerical data were analyzed using
student t test, and non-parametric Mann–Whitney test.
Signiﬁcance was deﬁned as P\0.05.
Results
For the 133 index patients in the ﬁrst part of the screening
study, the meanage atsymptom onset of 113 EOPD patients
was 40.6 ± 8.2 years (range 18–49 years) and the age at
the time of sampling was 50.2 ± 7.9 years (range
20–61 years). The mean age at symptom onset of 20 FPD
patients was 54.3 ± 7.8 years (range 48–66 years) and the
age at the time of sampling was 59.2 ± 8.9 years (range
54–77 years). The sample consisted of 65 men and 68
women.Forthe390late-onsetPDpatientsinthesecondpart
ofthestudy,themeanageatonsetwas56.8 ± 6.4 years,the
age at the time of sampling was 61.7 ± 9.1 years, and
51.7% of the patients were men.
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the 133 index patients in the ﬁrst screening set. One variant
was c.427C[G (Pro143Ala) in exon 1, which was found
in an EOPD patient (labeled as Y121) with an onset age of
42 years, and the other variant was c.906 ?3G[A in the
splicing junction between exon 3 and exon 4, which was
found in another EOPD patient (labeled as Y63) with an
onset age of 39 years (Fig. 1a). In the family of Y121, two
siblings carried the same heterozygous variant (Supple-
mentary Fig. 1, subjects II:2 and II:10). They did not show
motor symptoms of parkinsonism, suggesting that HTRA2
Pro143Ala variant did not obviously segregate with PD in
Y121 family. However, the UPSIT score of smelling test in
one carrier who was 71 years old (Supplementary Fig. 1,
subjects II:2) was markedly decreased (9/40) indicating
severe anosmia, implying a premotor stage of PD. These
two carriers should be closely followed up for motor
symptoms of PD. Of these two substitutions, Pro143Ala
was also observed in one late-onset PD patient from the
second screening study of 390 sporadic PD cases, but
the variant was absent in total 850 matched controls. The
frequency of this novel substitution was higher in PD
patients compared to controls (relative risk 2.3, 95% CI
1.5–2.8, P = 0.04). We did not screen the intronic variant,
c.906 ? 3G[A, in the second part of screening. Given
that PINK1 has been found to regulate HTRA2 (Plun-
Favreau et al. 2007), we also sequenced the entire PINK1
coding region and intron–exon boundaries in 2 probands
and 2 non-affected carriers of family Y121 with HTRA2
Pro143Ala variation, and one proband with HTRA2 c.906
?3G [A substitution. In addition, we checked the
reported SNCA mutations, such as A30P and A53T, LRRK2
mutations, such as R1441C/G/H and G2019S, and Parkin
mutations in the aforementioned 5 carriers with HTRA2
variants. No one has PINK1, Parkin and SNCA mutations.
The clinical symptoms of the three patients were similar to
typical Parkinsonism manifested as unilateral onset of
tremor, rigidity, bradykinesia, and good responses to
levodopa treatment. There were no atypical presentations,
such as dementia, psychiatric symptoms, cerebellar ataxia
or motor neuron disease, or rapid disease progression.
Speciﬁcally, the mean disease duration of these three
patients was 10.0 ± 5.3 years and the average Hoehn–
Yahr stage was between II and III, similar to the total study
cohort (mean disease duration: 9.8 ± 6.3 years, average
Hoehn–Yahr stage: between II and III). Additionally,
we also observed two intronic variants in our study:
rs10779958:A[C and rs2241028:G[A. Both variants
correspond to single nucleotide polymorphisms (SNPs)
with minor allele frequencies of more than 1% in controls
(Supplementary table 1).
The potential pathogenic variation in the exon–intron
boundary junction, c.906 ?3G [A, seems to disrupt
splicing efﬁcacy (http://www.fruitﬂy.org). To test the effect
of this variant allele on transcriptional activity, we per-
formed a q-PCR analysis. We found that the HTRA2 mRNA
expression level in case Y63 was signiﬁcantly decreased
compared to the age- and gender-matched control subjects
(Fig. 2a). Speciﬁcally, HTRA2 expression was only half that
of normal controls (controls: 100 ± 10.2%; PD subject
Y63: 55.4 ± 9.7%; P\0.001 by Mann–Whitney test).
Additionally, the RT-PCR analysis showed that the exon
2–exon 7 transcript was signiﬁcantly decreased in case Y63
as compared to the age-/gender-matched controls (Fig. 2b).
This ﬁnding suggests that c.906 ?3G[A alters the tran-
scriptional activity of HTRA2.
Y121      
c.427C>G 
(Pro143Ala)
Y63
c.906 +3 G>A 
H.sapiens
M.musculus
R.norvegicus
B.taurus
Pro143Ala
MLS
T
M
I
B
M
Serine protease PDZ
Pro143Ala
A
B
C
Fig. 1 HTRA2 substitutions identiﬁed in PD patients. a Forward
sequence chromatograms obtained by direct sequencing of the HTRA2
genomic sequence. The positions of the potential variations identiﬁed
in this study are indicated. Coding DNA is numbered relative to
coding DNA reference sequence NM_013247.4 and starts at trans-
lation initiation site. Protein is numbered relative to largest HTRA2
isoform NP_037379.1. b The mutated residue, 143, is found between
the IAP-binding motif (IBM) and the serine protease. MLS mito-
chondrial localizing sequence, TM predicted transmembrane domain
found in unprocessed HTRA2. The C-terminal PDZ domain is also
indicated. c Conservation of the HTRA2 protein residues targeted
by the potential mutations identiﬁed in our patients. The closest
homologues of the human HTRA2 protein were aligned using the
program Vector NTI
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123The other novel missense substitution, c.427 C[G
(Pro143Ala), targets the highly conservative region
between the inhibitor of apoptosis protein (IAP)-binding
motif (IBM) and the serine protease domain of the HTRA2
protein (Fig. 1b, c). In order to investigate the structural
impact of the Pro143Ala variant on the HTRA2 protein, a
molecular modeling analysis was performed. Residues
139–149 (PPASARSQYNF) were optimized and ten
mutation Pro143Ala models generated. By visually
inspecting all the models, the mutation model with the
lowest energy was selected. The Pro143Ala variant induces
a transformation of the shape of helix a1 compared to
HTRA2 (1LCY) (Fig. 3a, red circle indicates the helix a1).
Among the 11 optimized residues, the conformations of
A B
Exon 2-7
GAPDH
Con1 Con2 Y63
Fig. 2 Quantitative real-time and reverse-transcription PCR analysis
of HTRA2 c.906 ?3G [A. a Real-time PCR analysis of the c.906
?3G[A substitution in patient Y63. HTRA2 cDNA were ampliﬁed
from the whole venous blood of patient Y63 and seven age-/gender-
matched control subjects. The cDNA expression of HTRA2 was
shown as percentages relative to those of control subjects, averaged
from three independent experiments. Statistical analysis was per-
formed using ANOVA followed by the Mann–Whitney U test.
*P\0.01. b An agarose gel of PCR-ampliﬁed cDNA products of
HTRA2 exon 2-exon 7 cDNA for proband Y63 and two age/gender
matched-controls
protease domain
PDZ
Typ147
Arg144
Ala143
Pro143
Ser142
A B
CD
Fig. 3 Protein modeling of the
wild-type and variant HTRA2.
a Superposition of HTRA2
(purple, 1LCY) and the mutated
model Pro143Ala (cyan). The
optimized loop region of
residues 139–149
(PPASARSQYNF) is circled in
red. b A close-up view of
optimized residues 139–149.
Pro143 and Ala143 are shown
in orange and yellow,
respectively. Residues Ser142,
Arg144, and Typ147 with large
variations in two models are
shown in stick form. The
electrostatic potential surface
maps for HTRA2 (1LCY)
(c) and the c.427C[G
(Pro143Ala) substitution (d)
822 Hum Genet (2011) 130:817–827
123residues Ser142, Arg144, and Try147 varied signiﬁcantly,
whereas the other residues virtually remained at the same
place (Fig. 3b).
To examine the effect of the potential mutant allele on
the subcellular localization of HTRA2 protein, we per-
formed immunocytochemical analysis on neuronal cells
transfected with eGFP-tagged expression vectors contain-
ing either wild-type or Pro143Ala variant HTRA2. Con-
focal microscopy revealed that the localization of the
Pro143Ala variant HTRA2 was primarily cytoplasmic, co-
localizing with the mitochondrial markers (MitoTracker),
similar to the wild-type protein in both SH-SY5Y cells and
rat primary dopaminergic neurons (data not shown).
However, expressing Pro143Ala variant HTRA2 in pri-
mary dopaminergic neurons causes defects of neurite
arborization (Fig. 4a). The mean length of the neurite was
signiﬁcantly shorter in the Pro143Ala variant cells than
in the HTRA2 wild-type cells (59.19 ± 4.28 vs.
96.01 ± 5.60, P\0.01; Fig. 4b). Given that Lewy body
deposition is the main pathological hallmark of dopami-
nergic neurons in PD patients. We performed immunocy-
tochemical analysis to detect Lewy body deposition in the
rat primary dopaminergic neurons expressing either wild-
type or Pro143ala variant HTRA2 using anti-a-synuclein
antibody. We did not detect obvious a-synuclein-positive
aggregations in both wild-type and Pro143Ala variant
HTRA2-expression neurons (data not shown). Whereas
neurite degeneration is an early stage of cell death, we
hypothesize that Pro143Ala may cause neuronal death
through dysregulation of mitochondrial function.
To assess the effect of Pro143Ala variant HTRA2 on the
mitochondrial function, we characterized the MMP chan-
ges induced by rotenone, a mitochondria complex I
inhibitor, in SH-SY5Y cell lines expressing wild-type or
Pro143Ala variant HTRA2. Cells were exposed to various
concentrations (50, 100 or 300 nM) of rotenone for 48 h.
As shown in Fig. 5a, after 300 nM rotenone treatment, the
percentage of disrupted MMP is higher in cells transfected
vector HTRA2 WT Pro143Ala
50µm
0
20
40
60
80
100
A
B
**
Fig. 4 HTRA2 Pro143Ala variant induced neurite degeneration.
a Representative images of the rat primary dopaminergic neurons
expressing wild-type or variant HTRA2. Scale bar,5 0lm. b Quan-
tiﬁcation of the percentage of neurite length relative to vector control
in neurons expressing wild-type or variant HTRA2. Averages are the
mean ± SEM of neurite length. Signiﬁcance is compared by ANOVA
followed by the Mann–Whitney U test. **P\0.01
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123with the Pro143Ala variant HTRA2 than in the wild-type
cells (3.71 ± 0.12 vs. 1.3 ± 0.27, P\0.05). This is con-
ﬁrmed by electron microscopy analysis showing that
mitochondria of SH-SY5Y cells expressing wild-type
HTRA2 have partially lost their cristae, become swollen,
contained a dense particle and disrupted after 300 nM
rotenone treatment (Fig. 5c). Mitochondria were more
severely destroyed in Pro143Ala variant HTRA-transfected
SH-SY5Y cells with exposure of 300 nM rotenone
(Fig. 5d).
Moreover, the apoptosis was signiﬁcantly increased in
the HTRA2 Pro143Ala variant transfected cells comparing
to wild-type transfected cells after 300 nM rotenone
treatment (Fig 5b, 42.4 ± 3.9 vs. 23.6 ± 3.8%, P = 0.03).
Given that Pro143Ala is the only residue from the
potential phosphorylation site of HTRA2 protein for p38
stress kinase, the upstream kinase for HTRA2, and the
phosphorylation status of HTRA2 protein correlates with
its anti-apoptotic activity (Plun-Favreau et al. 2007), it is
therefore important to examine whether Pro143Ala
substitution affects the phosphorylation status of HTRA2
protein. We found that the protein level of phospho-
HTRA2 was elevated in Pro143Ala variant-expressing
cells, as compared to wild-type HTRA2 or vector control
(Fig. 6a, b). These results suggest that Pro143Ala variant,
through up-regulating phosphorylation level of HTRA2
protein, may directly or indirectly impair mitochondrial
integrity with resulting neuronal death.
Discussion
We evaluated the HTRA2 gene in a relatively large series
of Taiwanese patients with PD. In the ﬁrst screening set,
we did not ﬁnd a positive association between previously
reported SNPs and PD risk, which is consistent with a
recent report of large-scale mixed populations (Kru ¨ger
et al. 2009). In addition, we did not detect the reported
intronic risk variant, IVS5 ? 29T[A, in our study pop-
ulation (Wang et al. 2011). Notably, we identiﬁed two
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123novel substitutions (Pro143Ala and c.906 ?3G[A) in a
single heterozygous state in three PD patients, and these
substitutions were absent from all 850 controls. To assess
the genetic evidence for the pathogenicity of our identiﬁed
variations, we examined whether HTRA2 c.427 C[G
(Pro143Ala) segregates with disease in our index family
Y121. The clinical phenotypes of the proband included
typical PD features and a good response to levodopa
treatment. Two carriers did not exhibit parkinsonism fea-
tures at the time of the study. However, although the elder
carrier did not have parkinsonism features yet at the age of
71, the smelling test showed severe anosmia, suggesting a
pre-motor state of dopaminergic neuronal degeneration.
Both carriers need to be closely followed for both motor
and non-motor features of parkinsonism. Subsequently, we
genotyped c.427 C[G (Pro143Ala) in a large set of total
850 control subjects and identiﬁed no additional genetic
substitution. However, it is not easy to prove the patho-
genicity of our identiﬁed substitutions, especially as the
number of approached family members in our index family
was limited. Given the result that this substitution was not
observed in a total of 1,700 control chromosomes, we
suggest that either c.427 C[G (Pro143Ala) or c.906 ?3
G[A is a rare risk polymorphism in our population.
Although we did not perform cDNA or gene dosage
analysis to detect large duplications or deletions, given that
the HTRA2 mutations reported to date are missense muta-
tions, the chance that our study underestimated the
mutational frequency is relatively small. Therefore, either
point mutations or small deletions could be detected by the
method used in our current study.
Among these two novel substitutions we identiﬁed,
c.906 ?3G [A, which is located in the exon–intron
boundary junction, had signiﬁcantly decreased mRNA
expression compared to the age- and gender-matched
control subjects in the q-PCR analysis. This variant also
caused decreased exon 2-exon 7 transcript in the RT-PCR
analysis. This variation could dramatically change the
transcriptional activity or splicing ability of HTRA2
(Fig. 2a, b). However, because this variant is in the intron,
rather than in the exon, it is technically difﬁcult to con-
struct the expression plasmid for this HTRA2 intronic
variant. Therefore, we did not perform similar functional
studies as done in the Pro143Ala variant in the neuronal
cell lines. Further functional studies are warranted in cel-
lular or animal models to clarify the pathogenicity of this
intronic variation.
HTRA2 Pro143Ala is an evolutionarily highly con-
served amino acid residue (Fig. 1c) and is only one residue
from the potential phosphorylation site for p38 stress
kinase, the upstream kinase for HTRA2 (Plun-Favreau
et al. 2007). Using an in silico phosphorylation site pre-
diction tool, recent studies identiﬁed Ser142, near the
protease domain, and Ser400, in the PDZ domain, of
HTRA2 as two potential phosphorylation sites for proline-
directed serine/threonine kinases (Plun-Favreau et al.
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1232007). Among these two sites, protein levels of phos-
phorylated Ser142 HTRA2 is increased in brain samples
from patients with idiopathic PD and it is found to be
speciﬁcally phosphorylated in response to activation of the
p38 stress kinase. Ambiguously, the level of phopho-
HTRA2 at Ser142 site is decreased in familial PD patient
with PINK1 mutations, the upstream regulator of P38 and
HTRA2 (Plun-Favreau et al. 2007). The reason for this
condition is unclear. One of the possible mechanisms is
that, although the phosphorylation of HTRA2 is mediated
by the p38 pathway it is also dependent on the interaction
between HTRA2 and PINK1, possibly through a trimeric
protein complex. These observations suggest that the dys-
regulation of phospho-HTRA2 at Ser142 site contributes to
the development of PD. Our molecular modeling data
showed that the amino acid residue 143, the residue next to
Ser142, is situated at the beginning of helix a1 of the
HTRA2 protein, and the Pro143Ala substitution results in a
marked helix transformation (Fig. 3a) and affects the ori-
entation of Ser142 (Fig. 3b). Furthermore, electrostatic
potential surface maps show that the surface of this region
differs between wild-type and mutant HTRA2 (Fig. 3c, d).
This structural variation would impact the phosphorylation
of Ser142 by p38 kinase and may potentially decrease
cellular protection from oxidative stress. We therefore
propose that Pro143Ala HTRA2 may act through up-reg-
ulating the phosphorylation level of HTRA2 protein with
resulting mitochondrial dysfunction. Our in vitro ﬁndings
are in accordance with our hypothesis as evidenced by the
level of phosphorylated HTRA2, which is signiﬁcantly
increased in cells expressing Pro143Ala variant HTRA2
than wild-type HTRA2 (Fig. 6a, b). We further observed a
higher percentage of cells with disrupted MMP and a
higher rate of apoptosis in the cells expressing the
Pro143Ala variant compared to wild-type protein. Using a
cellular stress model, we revealed that the Pro143Ala
variant is associated with a greater rate of mitochondrial
dysfunction, mitochondrial morphology disruption and
apoptosis under conditions of increased oxidative stress
(300 nM rotenone) (Fig. 5a–d). Overall, our model pro-
vides compelling evidence to support our ﬁnding that the
Pro143Ala variant is biologically relevant to the pro-
apoptotic mechanism by disturbing mitochondrial function.
In conclusion, our data support a role for HTRA2 in PD
susceptibility in the Taiwanese population. The pathoge-
nicity of Pro143Ala variant is needed to be conﬁrmed by
further large-scale replication studies involving more
patients and controls in Asian populations. In addition, our
in vitro work showed that the Pro143Ala variant is bio-
logically relevant and may act through pro-apoptotic
mechanisms. Further in vivo work to unravel the patho-
physiological signiﬁcance of Pro143Ala substitution and its
relationship with mitochondrial dysfunction is warranted.
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